



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 17 July 2018 (#21)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices:

- **National Institute of Allergy and Infectious Diseases (NIAID) OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2018: Soliciting Proposals for Antimicrobial Products, Novel Vaccines and Technologies Against Category A, B, and C Agents, and Universal Influenza Vaccines** ([NOT-AI-18-048](#))
- Notice of Change to **Due Date** and Foreign Institutions Eligibility for Applications to RFA-HD-19-018: Using **Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research** (R21 - Clinical Trial Not Allowed) ([NOT-HD-18-014](#)) *Eunice Kennedy Shriver* National Institute of Child Health and Human Development.
- National Heart, Lung, and Blood Institute (NHLBI) Announces Participation in PA-17-444 "**Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)**" ([NOT-HL-18-621](#))
- Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in [PA-18-723](#) (R21) and [PA-18-722](#) (R01) "**Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health** (Clinical Trial Optional)" ([NOT-HL-18-640](#)) and ([NOT-HL-18-641](#))
- Notice of Information for HIV research priorities at the National Heart, Lung, and Blood Institute ([NOT-HL-18-642](#))

1. Detection of HIV for Self-Testing

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-17-471](#)

Type: R61/R33

Application Due Date: December 6, 2018, and December 6, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.

Budget: NIAID intends to commit \$2,640,000 in FY 2018 to fund 3-6 awards. NIMH intends to commit \$300,000 total cost in FY 2018. Future year amounts will depend on annual appropriations. Application budgets are limited to \$300,000 in direct costs per year in the R61 phase and \$500,000 in direct costs per year in the R33 phase. All F&A costs are excluded from this limit. Requested budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for an application submitted in response to this FOA cannot exceed five 5 years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

2. Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-850\)](#)
[\(PA-18-849\)](#)

Type: R21
R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.

Budget: R21: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. R01: Application budgets are not limited but need to reflect the actual needs of the proposed project.

3. Drug Transport Across the Blood-Testis and Blood-Epididymal Barriers (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-853\)](#)

Type: R61/R33

Application Due Date: November 27, 2018, November 27, 2019, November 27, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support in vivo research to elucidate the chemical features of non-native molecules that facilitate passage across the blood-testis and/or blood-epididymal barriers.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Christa* • Tel: 9838 • Email: cde.vries@sun.ac.za